Virax Biolabs Group Stock Today
| VRAX Stock | USD 1.69 0.18 9.63% |
PerformanceWeak
| Odds Of DistressLow
|
Virax Biolabs is trading at 1.69 as of the 25th of February 2025; that is 9.63 percent down since the beginning of the trading day. The stock's open price was 1.87. Virax Biolabs has about a 23 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 28th of October 2024 and ending today, the 25th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 21st of July 2022 | Category Healthcare | Classification Health Care |
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom. The company has 4.34 M outstanding shares of which 59.01 K shares are at this time shorted by private and institutional investors with about 0.15 trading days to cover. More on Virax Biolabs Group
Moving against Virax Stock
| 0.42 | RNAC | Cartesian Therapeutics Earnings Call Next Week | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Virax Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Virax Biolabs can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Virax Biolabs' financial leverage. It provides some insight into what part of Virax Biolabs' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Virax Biolabs Group (VRAX) is traded on NASDAQ Exchange in USA. It is located in BioCity Glasgow, Lanarkshire, United Kingdom, ML1 5UH and employs 17 people. Virax Biolabs is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.51 M. Virax Biolabs Group conducts business under Biotechnology sector and is part of Health Care industry. The entity has 4.34 M outstanding shares of which 59.01 K shares are at this time shorted by private and institutional investors with about 0.15 trading days to cover.
Virax Biolabs Group currently holds about 21.76 K in cash with (6.25 M) of positive cash flow from operations.
Check Virax Biolabs Probability Of Bankruptcy
Ownership AllocationVirax Biolabs Group has 6.63 % of its outstanding shares held by insiders and 6.72 % owned by institutional holders.
Check Virax Ownership Details
Virax Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Qube Research & Technologies | 2024-09-30 | 0.0 | |
| Virtu Financial Llc | 2024-09-30 | 0.0 | |
| Squarepoint Ops Llc | 2024-12-31 | 0.0 | |
| Hrt Financial Llc | 2024-09-30 | 0.0 | |
| Ubs Group Ag | 2024-12-31 | 37.9 K | |
| Xtx Topco Ltd | 2024-12-31 | 11.9 K | |
| Royal Bank Of Canada | 2024-12-31 | 10.4 K | |
| R Squared Ltd | 2024-12-31 | 2.7 K | |
| Headlands Technologies Llc | 2024-09-30 | 185 | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 100.0 | |
| Northwestern Mutual Wealth Management Co | 2024-12-31 | 20.0 |
Virax Biolabs Historical Income Statement
Virax Stock Against Markets
Virax Biolabs Corporate Management
| Tomasz George | Chief Officer | Profile | |
| Joel Yeung | Accounting Manager | Profile | |
| Nigel MSc | Chief Officer | Profile | |
| Cameron Shaw | COO Director | Profile | |
| James Wang | Head Sourcing | Profile | |
| James Foster | Chairman CEO | Profile |
Additional Tools for Virax Stock Analysis
When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.